Global Circulating Tumor Cells Ctc Liquid Biopsy Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,173.84 Million |
 Market Size (Forecast Year) |
USD 4,170.06 Million |
 CAGR |
% |
| Major Markets Players |
>全球循环肿瘤细胞 (CTC) 液体活检市场，按技术（CTC 检测方法、CTC 富集方法、体外正向选择、基于分子 (RNA) 的技术、功能性体外细胞侵袭试验、异种移植模型、微芯片、单螺旋微通道、负向选择和免疫细胞化学技术）、应用（癌症应用、非癌症应用、非侵入性产前检测 (NIPT)、器官移植、传染病检测）、临床应用（早期癌症筛查、诊断、治疗选择、治疗监测、预后和复发监测）、样品类型（血液、尿液、唾液、脑脊液、其他）、产品（试剂盒和试剂、采血管、设备或系统）、标本（血液、骨髓、其他体液）、最终用户（研究和学术机构、参考实验室和医院和医生实验室）——2023 年至 2030 年的行业趋势和预测。
循环肿瘤细胞 (CTC) 液体活检市场分析和规模
在 2023-2030 年的预测期内，推动循环肿瘤细胞 (CTC) 液体活检市场增长的关键因素包括：由于其有效性，对循环肿瘤细胞 (CTC) 液体活检的需求不断增长、由于各种遗传疾病导致的癌症患病率不断上升、酒精消费量不断增加以及生活方式的改变。除此之外，CTC 在患者转移筛查和新兴抗癌药物临床前研究中的使用率不断上升，也促进了市场的增长。此外，引入纳米技术以提高 CTC 分离和检测的灵敏度和效率，广泛采用基于 CTC 的液体活检以实现快速恢复，以及对微创 (MI) 诊断程序的需求不断增长，都极大地促进了市场的增长。
Data Bridge Market Research 分析，循环肿瘤细胞 (CTC) 液体活检市场在 2022 年的规模为 11.7384 亿美元，预计到 2030 年将达到 41.7006 亿美元，在 2023 年至 2030 年的预测期内的复合年增长率为 17.17%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
循环肿瘤细胞 (CTC) 液体活检市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In Vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Application, Non-Cancer Applications, Non-Invasive Prenatal Testing (NIPT), Organ Transplantation, Infectious Disease Testing), Clinical Application (Early Cancer Screening, Diagnosis, Therapy Selection, Treatment Monitoring, Prognosis and Recurrence Monitoring), Sample Type, (Blood, Urine, Saliva, Cerebrospinal Fluid, Others), Product (Kits & Reagents, Blood Collection Tubes, Devices or System), Specimen (Blood, Bone Marrow, Other Body Fluids), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
QIAGEN (Germany), Bio-Techne (U.S.), Precision Medical Group, LLC. (U.S.), Aviva Systems Biological Corporation (U.S.), Biocept, Inc. (U.S.), Fluxion Biosciences, Inc. (U.S.), Greiner Bio-One International GmbH (Austria) , Ikonisys (U.S.), Miltenyi Biotec (Germany), IVDiagnostics (U.S.), BioFluidica (U.S.), Canopus Medical (Sweden), Biolidics Limited (Singapore), Creativ MicroTech, Inc. (U.S.), LungLife AI, Inc. (U.S.), Epic Sciences (U.S.), Rarecells Diagnostics (France), ScreenCell (France), Menarini Silicon Biosystems (U.S.). |
|
Market Opportunities |
|
Market Definition
The liquid biopsy is a type of non-invasive blood test which identifies circulating tumor cells and tumor DNA fragments which are released in the blood by primary tumors and metastatic sites. It is an alternative to surgical biopsy procedure, and it allows surgeon to detect cancer at a very early stage. The circulating tumor cells function as a seed of metastases. The patients who have developed solid tumors it is found in them. The detection and quantification of tumor cells in the blood of cancer patients is allowed by the testing of circulating tumor cells. There are various types of biological phenotypes of circulating tumor cells (CTCs) such as stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity and due to which, a phase of isolation-enrichment is required in their detection.
Global Circulating Tumor Cells (CTC) Liquid Biopsy Dynamics
Drivers
- Rising prevalence of cancer
The rising prevalence of different types of cancer is boosting the market’s growth. The increasing number of cancer cases across the world is fuelling the demand of liquid biopsy. Breast cancer was the most common cancer 2020 with 2.26 million cases and further lung cancer with 2.21 million cases. The rising prevalence of cancer can be reduced through early detection of cancer and appropriate treatment. Circulating cancer cells are suitable for developing preclinical models, particularly 3D organoid cultures, for use in drug screening, disease modelling, genome editing, and organoid biobanks, thus significantly driving the market’s growth.
- Awareness initiatives by global health organizations and government
The governments in various countries and global health organizations are spreading awareness about cancer and other growing diseases. National Cancer Control program of WHO, is a public health program aiming to reduce the growing number of cancer deaths and improve the life of cancer patients. Furthermore, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), initiated by the US Centers for Diseases and Prevention (CDC) in 1991, provides breast cancer screening and diagnosis for uninsured and low-income patients in the US every year. The rising awareness in people about the effects and necessity to cure the diseases is increasing the liquid biopsy tests and treatments further driving the market’s growth.
Opportunities
- Growth opportunities in emerging countries
The developing countries such as India, Brazil, Turkey, Russia, South Africa, China, South Korea are offering major growth opportunities for liquid biopsy market. The major factors owing to the growth of liquid biopsy market in developing economies include improving healthcare infrastructure, higher cancer prevalence, large patient population, increasing disposable income, and growing medical tourism. Thus, there are number of opportunities for the market’s growth.
- Increasing R&D associated with liquid biopsy
The new research and development in liquid biopsies have revolutionized several related technologies, clinical oncology, devising personalized therapeutic regimens, offering easy tumor sampling, continuous monitoring by repeated sampling, and screening for therapeutic resistance. The increasing research and development is further increasing the demand of liquid biopsy which further increases the market’s growth.
Restraints/Challenges
- The lower sensitivity of certain liquid biopsies
In liquid biopsies certain procedures are technically challenging such as Detecting ctDNA because the levels of ctDNA of any given cancer mutation can be very low in the plasma of a cancer patient, after treatment or surgery. ctDNA is not applicable to all cancers, some tumor types are bad ctDNA shedders such as gliomas and sarcomas, and acts as an hurdle for ctDNA profiling. The reason for low ctDNA levels is not clear but is considered to be associated with tumor vascularity, location or the blood-brain barrier. Thus, the lower sensitivity of certain liquid biopsies is a major challenge for the market’s growth.
- Unclear reimbursement scenario
Limited reimbursement (non-coverage for panel-based tests) restricts the growth of liquid biopsy testing. The guidelines of NCD proved favorable for approval of Foundation One’s genomic profiling assay, but there are possibilities that it can work against other companies developing NGS-panel tests under LDT scenario. Multigene NGS tests have not secured FDA approval or reimbursement coverage, it is up to Medicare Administrative Contractors (MACs) to approve coverage when a company seeks a local coverage determination (LCD) if multigene NGS tests have not secured FDA approval or reimbursement coverage. These unclear reimbursement scenarios will be creating an unfavorable situation for liquid biopsy market’s growth.
This circulating tumor cells (CTC) liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the circulating tumor cells (CTC) liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2021, Myriad Genetics, Inc. announced that it has presented the data at San Antonio Breast Cancer Symposium and highlighted the value of genetic testing in breast cancer treatment. This will help Myriad Genetics, Inc. to advance the launch of novel product in the market. This advancement will further fuel the growth of liquid biopsy market’s growth.
- In February 2021, Menarini Silicon Biosystems announced the launch of CellMag product line for manual enrichment and staining of circulating tumor cells. This has helped Menarini Silicon Biosystems to increase its product line and will significantly boosts the market’s growth.
Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope
循环肿瘤细胞 (CTC) 液体活检市场根据技术、应用、临床应用、样本类型、产品、标本和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
技术
- CTC 检测方法
- CTC 富集方法
- 体外正向选择
- 基于分子（RNA）的技术
- 功能性体外细胞侵袭试验
- 异种移植 模型
- 微芯片
- 单螺旋微通道
- 负选择和免疫细胞化学技术
应用
- 癌症应用
- 肺癌
- 乳腺癌
- 结直肠癌
- 前列腺癌
- 黑色素瘤
- 其他癌症
- 非癌症应用
- 无创产前检测（NIPT）
- 器官移植
- 传染病检测
临床应用
- 早期癌症筛查
- 诊断
- 治疗选择
- 治疗监测
- 预后和复发监测
样品类型
- 血
- 尿
- 唾液
- 脑脊液
- 其他的
产品
- 试剂盒和试剂
- 采血管
- 设备或系统
标本
- 血
- 骨髓
- 其他体液
最终用户
- 研究与学术机构
- 参考实验室
- 医院
- 医师实验室
全球循环肿瘤细胞 (CTC) 液体活检市场区域分析/见解
对循环肿瘤细胞 (CTC) 液体活检市场进行了分析，并提供了市场规模见解和趋势、技术、应用、临床应用、样品类型、产品、标本和最终用户（如上所述）。
循环肿瘤细胞（CTC）液体活检市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
北美在全球循环肿瘤细胞 (CTC) 液体活检市场占据主导地位。 这主要是由于北美地区越来越多地采用液体活检来诊断癌症。美国癌症病例迅速增加，这促使北美在全球液体活检市场占据主导地位。
预计亚太地区将在 2023 年至 2030 年的预测期内实现增长。推动亚太地区市场增长的主要因素包括可支配收入的增加、对液体活检技术的认识不断提高、医院、诊所、诊断实验室越来越多地采用先进技术进行诊断以及医疗支出不断增加。此外，医院和诊断中心的普及率不断提高也进一步推动了亚太地区市场的增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球循环肿瘤细胞 (CTC) 液体活检市场份额分析
循环肿瘤细胞 (CTC) 液体活检市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对循环肿瘤细胞 (CTC) 液体活检市场的关注有关。
循环肿瘤细胞 (CTC) 液体活检市场的一些主要参与者包括：
- QIAGEN（德国）
- Bio-Techne (美国)
- Precision Medical Group, LLC.（美国）
- Aviva Systems Biological Corporation（美国）
- Biocept, Inc.（美国）
- Fluxion Biosciences, Inc.（美国）
- Greiner Bio-One International GmbH（奥地利）
- Ikonisys (美国)
- Miltenyi Biotec（德国）
- IVDiagnostics（美国）
- BioFluidica（美国）
- Canopus Medical（瑞典）
- Biolidics 有限公司 (新加坡)
- Creativ MicroTech, Inc.（美国）
- LungLife AI, Inc.（美国）
- Epic Sciences（美国）
- Rarecells Diagnostics（法国）
- ScreenCell (法国)
- Menarini Silicon Biosystems（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
